24.01.2019 | Research Article
Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation
Erschienen in: Frontiers of Medicine | Ausgabe 3/2019
Einloggen, um Zugang zu erhalten